Biosyent Inc
XTSX:RX

Watchlist Manager
Biosyent Inc Logo
Biosyent Inc
XTSX:RX
Watchlist
Price: 11.74 CAD 0.95%
Market Cap: 134.7m CAD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

RX Price Targets Summary
Biosyent Inc

Wall Street analysts forecast RX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RX is 13.26 CAD with a low forecast of 13.13 CAD and a high forecast of 13.65 CAD.

RX Lowest Forecast
Wall Street Target
13.13 CAD
12% Upside
RX Average Forecast
Wall Street Target
13.26 CAD
13% Upside
RX Highest Forecast
Wall Street Target
13.65 CAD
16% Upside
Lowest
Price Target
13.13 CAD
12% Upside
Average
Price Target
13.26 CAD
13% Upside
Highest
Price Target
13.65 CAD
16% Upside
Biosyent Inc Competitors:
Price Targets
603998
Hunan Fangsheng Pharmaceutical Co Ltd
20% Upside
APLLTD
Alembic Pharmaceuticals Ltd
6% Upside
2096
Simcere Pharmaceutical Group Ltd
20% Downside
MDWD
Mediwound Ltd
38% Upside
603998
Hunan Fangsheng Pharmaceutical Co Ltd
20% Upside
APLLTD
Alembic Pharmaceuticals Ltd
6% Upside
2096
Simcere Pharmaceutical Group Ltd
20% Downside
MDWD
Mediwound Ltd
38% Upside
SUNPHARMA
Sun Pharmaceutical Industries Ltd
20% Upside
300401
Zhejiang Garden Bio-chemical High-tech Co Ltd
20% Upside
4502
Takeda Pharmaceutical Co Ltd
20% Upside

Revenue
Forecast

Revenue Estimate
Biosyent Inc

For the last 13 years the compound annual growth rate for Biosyent Inc's revenue is 21%. The projected CAGR for the next 3 years is 11%.

21%
Past Growth
11%
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Biosyent Inc

For the last 13 years the compound annual growth rate for Biosyent Inc's operating income is 26%. The projected CAGR for the next 5 years is -9%.

26%
Past Growth
-9%
Estimated Growth
Estimates Accuracy
1%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Biosyent Inc

For the last 13 years the compound annual growth rate for Biosyent Inc's net income is 25%. The projected CAGR for the next 3 years is 15%.

25%
Past Growth
15%
Estimated Growth
Estimates Accuracy
27%
Average Beat
What are analyst estimates?

See Also

Summary
RX intrinsic value, competitors valuation, and company profile.
DCF Valuation
RX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
RX stock valuation using valuation multiples.
Wall Street Estimates
RX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
RX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is RX's stock price target?
Price Target
13.26 CAD

According to Wall Street analysts, the average 1-year price target for RX is 13.26 CAD with a low forecast of 13.13 CAD and a high forecast of 13.65 CAD.

What is Biosyent Inc's Revenue forecast?
Projected CAGR
11%

For the last 13 years the compound annual growth rate for Biosyent Inc's revenue is 21%. The projected CAGR for the next 3 years is 11%.

What is Biosyent Inc's Operating Income forecast?
Projected CAGR
-9%

For the last 13 years the compound annual growth rate for Biosyent Inc's operating income is 26%. The projected CAGR for the next 5 years is -9%.

What is Biosyent Inc's Net Income forecast?
Projected CAGR
15%

For the last 13 years the compound annual growth rate for Biosyent Inc's net income is 25%. The projected CAGR for the next 3 years is 15%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 259,600+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.